Proposed interaction of some novel antidepressant pyrazolines against monoamine oxidase isoforms. Molecular docking studies and PASS assisted in silico approach

Biomedicine and Aging Pathology

Volumn 4, Issue 4, 2014, Pages 297-301

  Mathew, Bijo ^a   Suresh, Jerad ^b   Anbazhagan, S ^c   Dev, Sanal ^d  

^a Department of Pharmaceutical Chemistry   (India)

^b MADRAS MEDICAL COLLEGE   (India)

^c Surya School of Pharmacy   (India)

^d BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Antidepressant; Molecular docking; Monoamine oxidase; PASS; Pyrazoline

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); PYRAZOLINE DERIVATIVE;

ANTIDEPRESSANT ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; COMPUTER MODEL; DRUG PROTEIN BINDING; DRUG SYNTHESIS; MOLECULAR DOCKING;

EID: 84908354981     PISSN: 22105220     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomag.2014.07.011     Document Type: Article

References (20)

1. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behaviour. Annu Rev Neurosci 1999;22: 197-217.
2. Bach AWJ, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, et al. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci U S A 1988;85: 4934-8.
3. Gokhan N, Yesilada A, Ucüar G, Erol K, Bilgin AA. 1-Nsubstitutedthiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: Synthesis and evaluation as MAO inhibitors. Arch Pharm (Weinheim) 2003;336: 362-71.
4. Chimenti F, Maccioni E, Secci D, Bolasco A, Chimenti P, Granese A, et al. Synthesis, Molecular Modeling Studies, and Selective Inhibitory Activity against Monoamine Oxidase of 1-Thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)- pyr-azole derivatives. J Med Chem 2005;48: 7122-33.
5. Ucar G, Gokhanb N, Yesilada A, Bilgin AA. 1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: A novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases. Neurosci Lett 2005;382: 327-31.
6. Karuppasamy M, Mahapatra S, Yabanoglu S, Ucar G, Sinha BN, Basu A, et al. Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies. Bioorg Med Chem 2010;18: 1875-81.
7. Chimenti F, Carradori S, Secci D, Bolasco A, Bizzarri B, Chimenti P, et al. Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives. Eur J Med Chem 2010;45: 800-4.
8. Goksen US, Ciftci SY, Ercan A, Yelekci K, Ucar G, Kelekci NG. Evaluation of selective MAO inhibitory activities of some novel pyrazolines derivatives. J Neural Transm 2013;120: 863-73.
9. Kumar A, Jain S, Parle M, Jain N, Kumar P. Aryl-1-phenyl-1h-pyrazol derivatives as new multitarget directed ligands for the treatment of alzheimer's disease, with acetylcholinesterase and monoamine oxidase inhibitory properties. EXCLI J 2013;12: 1030-42.
10. Mathew B, Suresh J, Anbazhagan S, Mathew GE, Pyrazoline:. A promising scaffold for the inhibition of Monoamine oxidase. Cent Nerv Syst agents Med Chem 2013;13: 195-206.
11. Mathew B, Suresh J, Anbazhagan S. Synthesis, preclinical evaluation and antidepressant activity of 5-substituted phenyl-3-(thiophen-2-yl)-4, 5-dihydro-1h-pyrazole-1-carbothioamides. EXCLI J 2014;13: 437-45.
12. Poroikov VV, Filimonov DA, Ihlenfeldt WD, Gloriozova TA, Lagunin AA, Borodina YV, et al. PASS biological activity spectrum predictions in the enhanced open NCI Database Browser. J Chem Inform Comput Sci 2003;4: 228-36.
13. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. Autodock4 and Auto Dock Tools4: automated docking with selective receptor flexibility. J Comput Chem 2009;16: 2785-91.
14. De Colibus L, Li M, Binda C, Lustig A, Edmondson DE, Mattevi A. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc Natl Acad Sci U S A 2005;106: 12684-9.
15. Nayak BV, Ciftci-Yabanoglu S, Singh S, Jagrat M, Sinha BN, Ucar G, et al. Monoamine oxidase inhibitory activity of 3,5-biaryl-4,5-dihydro-1H-pyrazole-1-carboxylate derivatives. Eur J Med Chem 2013;69: 762-7.
16. Abdelhafez OM, Amin KM, Ali HI, Abdalla MM, Batran RZ. Synthesis of new 7-oxycoumarin derivatives as potent and selective monoamine oxidase-A inhibitors. J Med Chem 2012;55: 10424-36.
17. Beula SJ, Raj VBA, Mathew B. Isolation and molecular recognization of 6-prenyl apigenin towards MAO-Aas the active principle of seeds of Achyranthes aspera. Biomed Prev Nutr 2014, http://dx.doi.org/10.1016/j.bionut.2014.03.003 [online].
18. Abdelhafez OM, Amin KM, Ali HI, Abdalla MM, Batran RZ. Monoamine oxidase A and B inhibiting effect and molecular modeling of some synthesized coumarin derivatives. Neurochem Int 2013;62: 198-209.
19. Li PZ, Tian HL, Zhai HL, Deng FF, Xie MH, Zhang XY. Molecular modeling study on the structural basis of binding mechanism of C6-substituted phthalides with monoamine oxidases. Med Chem Res 2014, http://dx.doi.org/10.1007/s00044-014-0941-0 [online].
20. Jagrat M, Behera J, Yabanoglu S, Ercan A, Ucar G, Sinha BN, et al. Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies. Bioorg Med Chem Lett 2011;21: 4296-300.